SCHEMBL2089672

SCHEMBL2089672

[CH2]CCOCc1ccc(Cl)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.39
GRM2 Q14416 1/20 0.36
GRM3 Q14832 1/20 0.36
KDM5A P29375 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
DRD4 P21917 5/20 0.34
SIGMAR1 Q99720 5/20 0.34
DRD3 P35462 1/20 0.34
TMEM97 Q5BJF2 1/20 0.34
GPR84 Q9NQS5 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
F9 P00740 1/20 0.33
F10 P00742 1/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6236937 0.83 IDO1 (0.57) IDO1MAPTSIGMAR1
SCHEMBL6022845 0.79 IDO1 (0.37) IDO1GRM2GRM3KDM5AKDM5B
SCHEMBL10823078 0.77 PNMT (0.45) IDO1GRM2GRM3MAPTMAPK1
SCHEMBL3746892 0.77 MAPT (0.45) IDO1GRM2GRM3MAPTMAPK1
SCHEMBL22889496 0.76 IDO1 (0.42) IDO1GRM2GRM3KDM5AKDM5B
SCHEMBL27532057 0.75 IDO1 (0.39) IDO1GRM2GRM3KDM5AKDM5B
SCHEMBL5977520 0.75 IDO1 (0.50) IDO1MAPTMAPK1
SCHEMBL5981060 0.75 IDO1 (0.50) IDO1
SCHEMBL95960 0.73 GPR84 (0.50) GPR84HRH3PPARGPPARA
SCHEMBL20378901 0.73 KDM5A (0.38) GRM2GRM3KDM5AKDM5BDRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 IDO1 2665/4885GRM2 146/4885GRM3 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.